The cell cycle regulates growth and differentiation, and defects in cell cycle control are a hallmark of cancer development[@b1]. Phase progression is principally regulated by Cyclins, Cyclin-dependent kinases (CDKs), and CDK inhibitors (CKIs)[@b2]. Cyclins and CDKs form complexes regulating cell growth by cell cycle control, whereas CKIs inhibit the activities of the complexes and induce cell cycle arrest[@b3],[@b4]. P21 protein belongs to the Cip/Kip family of CKIs and inhibits the phosphorylation of retinoblastoma (Rb) protein by interfering with cyclin E--CDK2 or cyclin A--CDK2 complex[@b5],[@b6].

P21 (Cdkn1a/Waf1/Cip1) is encoded by the CDKN1A locus on chromosome 6p21.2 and has a p53 transcriptional regulatory motif. Studies have shown that *p21* is a critical downstream effector in the p53-specific pathway of growth control, and the expression of *p21* is directly regulated by p53 in response to DNA damage, leading to cell cycle arrest at the G~1~/S checkpoint[@b7]. As p21 inhibits proliferation[@b8] and acts as one of the major transcriptional targets of *p53*[@b7], it was initially considered as a potential tumor suppressor. However, studies have also reported that *p21* could act as an Oncogene because of its antiapoptotic activities[@b9]--[@b11]. Alterations in *p21* expression have been observed in a wide variety of cancers, including breast, lung, cervical, ovarian, liver, uterine, and head and neck cancers[@b12]--[@b17], indicating the importance of *p21* in Carcinogenesis.

Although the involvement of *p21* in tumor formation is evident, mutations in *p21* are very rare[@b18],[@b19]. Thus, most reports focus on genetic variants of *p21,* and genotypes of some functional polymorphisms have shown to be associated with a high risk of different types of cancer[@b20]--[@b22]. The most frequently investigated polymorphism of *p21* is Ser31Arg (rs1801270C \> A), with a base change from C to A resulting in a non-synonymous serine to arginine substitution in the protein[@b23], causing a loss of the *Blpl* restriction site and affecting the DNA-binding zinc finger motif[@b22]. Hence, it is likely that *p21* Ser31Arg polymorphism may result in the alteration of *p21* e xpression and/or activity, thereby affecting susceptibility to cancer.

Many molecular epidemiological studies have been conducted to evaluate the effect of the *p21* Ser31Arg polymorphism on cancer risk[@b19],[@b24]--[@b70]. The results, however, remain conflicting, and the underlying heterogeneity between studies still needs to be explored. To estimate the overall cancer risk associated with the *p21* Ser31Arg polymorphism and to quantify potential between-study heterogeneity, we conducted a systematic meta-analysis by including the most recent and relevant studies focusing on the association between the *p21* Ser31Arg polymorphism and cancer risk.

Materials and Methods {#s2}
=====================

Identification and eligibility of relevant references {#s2a}
-----------------------------------------------------

We included all references of the case-control studies written in English and published to date on the association between the *p21* Ser31Arg polymorphism and cancer risk. Two electronic databases (MEDLINE and EMBASE) were searched (last search update October 2010, using the search terms "*p21*" or "CDKN1A", "cancer" or "carcinoma", and "polymorphism" or "variant") to identify eligible references. Additional references were identified by a hand search of original papers or reviews. If studies had overlapping subjects, only the one with the larger or largest sample size was selected. Furthermore, the studies including subjects with family history or cancer-prone predisposition were excluded.

Data extraction {#s2b}
---------------

The following information was extracted from each report: author, year of publication, country of origin, ethnicity, demographics, cancer type, and detail genotyping information and source of controls (population-based and hospital-based). For studies including subjects of different racial descents, data were extracted separately for each race (categorized as Caucasian, Asian, and others).

Statistical analyses {#s2c}
--------------------

Genotype frequency was collected from each study to evaluate the risk of cancers \[odds ratios (ORs) and 95% confidence intervals (CI)\]. For all studies, we evaluated the effects of variant genotypes including Arg/Ser and Arg/Arg, compared with the wild-type Ser/Ser genotype, respectively. Then we calculated the ORs and 95% CI for both dominant and recessive genetic models of the variant Arg allele. In addition, we conducted stratification analysis by tumor type (if one cancer type was investigated in less than 3 studies, it would be merged into the "other cancers" group), ethnicity, control source, matching status (yes or no), and sample size ( \< 500, 500 to 1000, and \> 1000). Smoking-related cancers included lung, bladder, head and neck, kidney, and pancreatic cancers; estrogen-related cancers included breast, cervical, and ovarian cancers.

The *χ*^2^-based *Q* statistic test was used to assess between-study heterogeneity, and it was considered significant if *P* \< 0.05[@b71]. The fixed-effects model and the random-effects model were respectively performed to combine values from each of the studies based on the Mantel-Haenszel method and the DerSimonian and Laird method[@b72]. When the effects were assumed to be homogenous, the fixed-effects model was then used; otherwise, the random-effects model was more appropriate. The inverted funnel plots and Egger\'s test were used to investigate publication bias (linear regression analysis)[@b73]. The deviation of genotype distribution from Hardy-Weinberg equilibrium (HWE) among controls was also examined by a goodness-of-fit *χ*^2^ test. All analyses were conducted using Review Manage (v.5.0) and Stata 10.0. *P* values were two-sided.

Results {#s3}
=======

Characteristics of studies {#s3a}
--------------------------

A total of 48 publications examined the relationship between *p21* Ser31Arg polymorphism and cancer risk. Two studies[@b24],[@b25] were excluded because they investigated the same or a subset population of reported articles[@b65],[@b30]. Another two were also excluded because they did not present detailed genotyping information[@b69] or had cancer-prone predisposition[@b70]. The studies investigating different cancers[@b38], multiple ethnicity[@b26], or multi-center collaboration[@b30] were separated into multiple studies in subgroup analysis. In addition, three studies [@b48],[@b61],[@b68] that only provided the total number of variant genotypes (Arg/Ser and Arg/Arg) were included in the analysis for the dominant model but not for other genetic models. Finally, our meta-analysis consisted of 44 publications including 59 case-control studies: 20 breast cancer studies, 5 lung cancer studies, 6 head and neck cancer studies, 7 cervical cancer studies, 3 colorectal cancer studies, 3 skin cancer studies, 5 gastric and esophageal cancer studies, and 10 studies of other cancers ([Table 1](#cjc-30-04-254-t01){ref-type="table"}). Among the 59 studies, 28 were conducted in Caucasian descents, 28 were conducted in Asian descents, 2 were conducted in other descents, and the remaining one by Keshava *et al*.[@b26] was divided into two subgroups (Caucasians and other ethnicity), because it included multiple ethnicities. In addition, 11 studies were population-based and 48 were hospital-based; 26 did not provide matching information, while 33 were matched by age, sex, and/or geographic region. The polymerase chain reaction-restriction fragment length polymorphism assay (PCR-RFLP) was the most frequently used method for genotyping. Some other methods were also applied, such as direct sequencing, Taqman, and SNaPshot ([Table 1](#cjc-30-04-254-t01){ref-type="table"}). Overall, most studies indicated that the distribution of genotypes in controls was consistent with HWE with the exception of 6 studies[@b19],[@b26],[@b40],[@b43],[@b47],[@b59].

###### Characteristics of the 44 references included in the meta-analysis

  Reference                      Year   Country       Ethnicity                 Cancer type             Sample size (case/control)   Matching (yes/no)   Genotyping method                              Source of control
  ----------------------------- ------ ---------- ----------------- ----------------------------------- ---------------------------- ------------------- ---------------------------------------------- -------------------
  Keshava *et al*.[@b26]         2002     USA         Multiple                 Breast cancer            160/327                      Yes                 PCR-RFLP                                       Hospital
  Ma *et al*.[@b27]              2006    China          Asian                  Breast cancer            368/467                      Yes                 PCR-RFLP                                       Hospital
  Tarasov *et al*.[@b28]         2006    Russia       Caucasian                Breast cancer            151/191                      No                  PCR-RFLP and dCAPs                             Hospital
  Staalesen *et al*.[@b29]       2006    Norway       Caucasian                Breast cancer            547/1006                     No                  Sequencing                                     Hospital
  Cox *et al*.[@b30]             2007   Multiple   Caucasian/Asian             Breast cancer            18 290/22670                 Both                Multiple methods                               Both
  MARIE-GENICA[@b31]             2010   Germany       Caucasian                Breast cancer            3140/5472                    Yes                 MALDI-TOF MS and PCR-based fragment analyses   Population
  Sjalander *et al*.[@b32]       1996    Sweden       Caucasian                 Lung cancer             144/761                      No                  PCR-RFLP                                       Hospital
  Shih *et al*.[@b33]            2000    China          Asian                   Lung cancer             155/189                      Yes                 PCR-RFLP                                       Hospital
  Su *et al*.[@b34]              2003     USA         Caucasian                 Lung cancer             1069/1220                    No                  PCR-RFLP                                       Hospital
  Popanda *et al*.[@b35]         2007   Germany       Caucasian                 Lung cancer             402/403                      No                  Fluorescence-based melting-curve               Hospital
  Choi *et al.*[@b36]            2008    Korea          Asian                   Lung cancer             549/533                      Yes                 PCR and sequencing                             Hospital
  Sun *et al*.[@b19]             1995    China          Asian              Nasopharyngeal cancer        76/66                        No                  PCR-SSCP direct sequencing                     Hospital
  Tsai *et al*.[@b37]            2002    China          Asian              Nasopharyngeal cancer        47/119                       No                  PCR-RFLP                                       Hospital
  Rodrigues *et al*.[@b38]       2003    Brazil       Caucasian      Head and neck cancer; skin cancer  73/104;46/104                No                  PCR-SSCP                                       Hospital
  Li *et al*.[@b39]              2005     USA         Caucasian            Head and neck cancer         712/1222                     Yes                 PCR-RFLP                                       Hospital
  Bau *et al*.[@b40]             2007    China          Asian                   Oral cancer             137/105                      Yes                 PCR-RFLP                                       Hospital
  Gomes *et al*.[@b41]           2008    Brazil         Mixed                   Oral cancer             80/80                        Yes                 PCR-RFLP                                       Hospital
  Roh *et al*.[@b42]             2001    Korea          Asian                 Cervical cancer           111/98                       No                  PCR-RFLP                                       Hospital
  Harima *et al*.[@b43]          2001    Japan          Asian                 Cervical cancer           66/108                       No                  Sequencing                                     Hospital
  Lee *et al*.[@b44]             2004    Korea          Asian                 Cervical cancer           185/345                      No                  SNaPshot assay                                 Hospital
  Lee *et al*.[@b45]             2004    Korea          Asian                 Cervical cancer           81/86                        No                  PCR-RFLP                                       Hospital
  Bhattacharya *et al*.[@b46]    2005    India          Asian                 Cervical cancer           148/191                      No                  PCR-RFLP                                       Hospital
  Tian *et al*.[@b47]            2009    China          Asian                 Cervical cancer           317/353                      Yes                 MAMA-PCR                                       Hospital
  Roh *et al*.[@b48]             2010    Korea          Asian             Cervical adenocarcinoma       53/286                       No                  PCR-RFLP                                       Hospital
  Wu *et al*.[@b49]              2003    China          Asian                Esophageal cancer          128/178                      Yes                 PCR-RFLP                                       Hospital
  Wu *et al*.[@b50]              2004    China          Asian                 Gastric cancer            89/192                       Yes                 PCR-RFLP                                       Hospital
  Lai *et al*.[@b51]             2005    China          Asian                 Gastric cancer            123/119                      No                  PCR-RFLP                                       Hospital
  Taghavi *et al*.[@b52]         2010     Iran          Asian                Esophageal cancer          126/100                      Yes                 PCR-RFLP                                       Hospital
  Yang *et al*.[@b53]            2010    China          Asian                Esophageal cancer          80/200                       Yes                 Sequencing                                     Hospital
  Polakova *et al*.[@b54]        2009   Germany       Caucasian              Colorectal cancer          612/611                      Yes                 Taqman                                         Hospital
  Liu *et al*.[@b55]             2010    China          Asian                Colorectal cancer          373/838                      No                  PCR-RFLP                                       Population
  Cacina *et al*.[@b56]          2010    Turkey       Caucasian              Colorectal cancer          53/64                        Yes                 PCR-RFLP                                       Hospital
  Konishi *et al*.[@b57]         2000    Japan          Asian                   Skin cancer             113/165                      No                  PCR-RFLP                                       Hospital
  Li *et al*.[@b58]              2008     USA         Caucasian             Cutaneous melanoma          805/838                      Yes                 PCR-RFLP                                       Hospital
  Hachiya *et al*.[@b59]         1999    Japan          Asian               Endometrial cancer          54/55                        Yes                 Dot Blot Hybridization                         Hospital
  Chen *et al*.[@b60]            2002    China          Asian                 Bladder cancer            53/119                       No                  PCR-RFLP                                       Hospital
  Roh *et al*.[@b61]             2004    Korea          Asian               Endometrial cancer          95/285                       No                  PCR-RFLP                                       Hospital
  Hishida *et al*.[@b62]         2004    Japan          Asian             Non-Hodgkin\'s lymphoma       103/440                      No                  Duplex PCR-CTPP                                Hospital
  Huang *et al*.[@b63]           2004    China          Asian                 Prostate cancer           200/247                      Yes                 PCR-RFLP                                       Hospital
  Hirata *et al*.[@b64]          2007    Japan          Asian              Renal cell carcinoma         200/200                      Yes                 PCR-RFLP                                       Hospital
  Gayther *et al*.[@b65]         2007   Multiple      Caucasian               Ovarian cancer            1491/2463                    Yes                 Taqman                                         Population
  Rajaraman *et al*.[@b66]       2007     USA           Mixed                   Brain tumor             594/529                      Yes                 Taqman                                         Hospital
  Chung *et al*.[@b67]           2008    China          Asian              Urothelial carcinoma         169/402                      Yes                 PCR-RFLP                                       Hospital
  Chen *et al*.[@b68]            2010     USA         Caucasian              Pancreatic cancer          509/462                      Yes                 Pyrosequencing and PCR-RFLP                    Hospital

PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphisms; dCAPs, derived cleaved amplified polymorphic sequences; MALDI-TOF MS, matrix assisted laser desorption ionisation time-of-flight mass spectrometry; SSCP, single strand conformation polymorphism; MAMA, mismatch amplification mutation assay; CTPP, confronting two-pair primers.

![Forest plot (random-effects model) of overall cancer risk associated with the *p21* codon 31 polymorphism: Arg/Arg vs. Ser/Ser. Compared to Ser/Ser, Arg/Arg had a borderline association with increased risk of all types of cancer.](cjc-30-04-254-g001){#cjc-30-04-254-g001}

Quantitative synthesis {#s3b}
----------------------

The *p21* 31Arg allele frequency varied in different ethnicities, ranging from 0.04 in a Caucasian population[@b30] to 0.54 in an Asian population[@b51]. When the eligible studies were pooled into the meta-analysis, the variant genotypes of *p21* Ser31Arg were significantly associated with an increased cancer risk. Specifically, compared to the wild-type homozygotes (31Ser/Ser), the variant homozygotes (31Arg/Arg) had a borderline increased risk of all types of cancers (OR = 1.17, 95% CI = 0.99 to 1.37, P = 0.0002 for heterogeneity test), and the association was significant in the recessive genetic model \[Arg/Arg vs. (Ser/Ser + Arg/Ser): OR = 1.16, 95% CI = 1.01 to 1.33, *P* = 0.0001 for heterogeneity test\] ([Figures 1](#cjc-30-04-254-g001){ref-type="fig"} and [2](#cjc-30-04-254-g002){ref-type="fig"}). However, such associations were not found for heterozygous comparison or for dominant model comparison (heterozygote comparison: OR = 1.01, 95% CI = 0.94 to 1.08, *P* \< 0.0001 for the heterogeneity test; dominant model comparison: OR = 0.98, 95% CI = 0.89 to 1.08, *P* \< 0.0001 for the heterogeneity test).

In stratified analysis by tumor type, recessive model comparison with the heterogeneity test showed that individuals with variant homozygous genotypes (31Arg/Arg) had a higher risk for colorectal cancer (OR = 1.39, 95% CI = 1.03 to 1.08, *P* = 0.25) and estrogen-related cancer (OR = 1.27, 95% CI = 1.01 to 1.60, *P* = 0.002), but not for other cancers ([Table 2](#cjc-30-04-254-t02){ref-type="table"}). Furthermore, recessive model comparison for the heterogeneity test showed that the risk effect of variant homozygotes (31Arg/Arg) remained significant in studies with Caucasian subjects (OR = 1.41, 95% CI = 1.14 to 1.73, *P* = 0.34), population-based controls (OR = 1.36, 95% CI = 1.11 to 1.67, *P* = 0.06), matching design (OR = 1.21, 95% CI = 1.01 to 1.45, *P* = 0.002), and sample size more than 1000 (OR =1.18, 95% CI = 1.01 to 1.37, *P* = 0.08).

![Forest plot (random-effects model) of overall cancer risk associated with the *p21* codon 31 polymorphism: Arg/Arg vs. (Arg/Ser+ Ser/Ser). Compared to Arg/Ser + Ser/Ser, Arg/Arg had an association with increased risk of all types of cancer.](cjc-30-04-254-g002){#cjc-30-04-254-g002}

Heterogeneity and sensitivity analyses {#s3c}
--------------------------------------

In the recessive model comparison, heterogeneity among all studies on the *p21* Ser31Arg polymorphism and cancer risk was observed (*χ*^2^ = 98.56, *P* = 0.0001). We evaluated the source of heterogeneity by tumor type, ethnicity, control source, matching status, and sample size, and found that tumor type contributed to substantial heterogeneity (*χ*^2^ = 21.83, *P* = 0.003), but not ethnicity, control source, matching status, and sample size. The leave-one-out sensitivity analysis indicated that no single study changed the pooled ORs qualitatively. Furthermore, the exclusion of 6 studies [@b19],[@b28],[@b40],[@b43],[@b47],[@b59], whose genotype distributions deviated from HWE, did not affect the results of the meta-analysis (OR = 1.16, 95% CI = 1.01 to 1.34, *P* = 0.0004).

###### Summary ORs for association between the *p21* Ser31Arg polymorphism and cancer risk

  Subgroup                        Comparisons  Cases/Controls   Arg/Arg vs. (Arg/Ser + Ser/Ser) OR (95% CI)^c^   *P*^d^
  ------------------------------ ------------- ---------------- ------------------------------------------------ -----------
  Total^a^                            56       32 420/43 960    1.16 (1.01--1.33)                                0.0001
   Tumor type                                                                                                    
   Breast cancer                      20       22 656/30 133    1.25 (0.95--1.63)                                0.03
   Lung cancer                         5       2319/3106        0.92 (0.73--1.17)                                0.88
   Head and neck cancer                6       1125/1696        1.16 (0.79--1.72)                                0.63
   Cervical cancer                     6       908/1181         1.40 (0.85--2.28)                                0.005
   Colorectal cancer                   3       1038/1513        1.39 (1.03--1.87)                                0.25
   Skin cancer                         3       964/1107         0.64 (0.36--1.16)                                0.15
   Gastric / esophageal cancer         5       546/769          0.78 (0.58--1.03)                                0.25
   Other cancers                       8       2864/4455        1.43 (1.18--1.73)                                0.08
  Smoking--related cancer             12       3574/4936        1.05 (0.88--1.27)                                0.10
  Estrogen--related cancer            29       25 055/33 777    1.27 (1.01--1.60)                                0.002
  Ethnicity^b^                                                                                                   
   Caucasian                          28       27 184/36 960    1.41 (1.14--1.73)                                0.34
   Asian                              26       4495/6251        1.09 (0.92--1.28)                                \< 0.0001
   Others                              3       741/749          0.87 (0.53--1.42)                                0.11
  Control source                                                                                                 
   Population                         11       17623/26454      1.36 (1.11--1.67)                                0.06
   Hospital                           45       14797/17506      1.15 (0.99--1.33)                                0.0008
  Matching status                                                                                                
   Yes                                32       23 809/27 929    1.21 (1.01--1.45)                                0.002
   No                                 24       8611/16031       1.09 (0.88--1.35)                                0.01
  Sample size                                                                                                    
   \< 500                             25       2653/3827        1.05 (0.85--1.30)                                0.002
   500--1000                           8       2455/3522        1.21 (0.87--1.68)                                0.01
   \> 1000                            23       27 312/36 611    1.18 (1.01--1.37)                                0.08

OR, odds ratio; CI, confidence interval. ^a^Three references that only provided the total number of Arg/Ser and Arg/Arg were excluded from the analysis for the recessive comparison \[Arg/Arg vs. (Arg/Ser+Ser/Ser)\]. ^b^0ne study by Keshava et al included multiple ethnicities. ^c^Random effect model was used when *P* value for heterogeneity test \< 0.05; otherwise, fix effect model was used. ^d^Test for heterogeneity.

Publication bias {#s3d}
----------------

Funnel plot and Egger\'s test were conducted to access the publication bias of all studies. The shapes of the funnel plots seemed symmetrical ([Figure 3](#cjc-30-04-254-g003){ref-type="fig"}), suggesting that there was no obvious publication bias. Egger\'s test was used to provide further statistical evidence; similarly, we did not find significant publication bias in this meta-analysis (*t* = 0.95, *P* = 0.345).

Discussion {#s4}
==========

On the basis of 44 independent publications, our meta-analysis provided statistical evidence that variant homozygous Arg/Arg genotype of *p21* was significantly associated with an increased risk of cancers, particularly of colorectal cancer and estrogen-related cancer. The stratification analysis also showed that the risk effect of Arg/Arg was more prominent in studies with Caucasian subjects, population-based controls, matching design, and larger sample sizes.

P21 is a Cyclin-dependent kinase inhibitor, causing cell cycle arrest by inhibiting the G~1~ to S phase checkpoint, and it is up-regulated by the tumor suppressor protein P53[@b7]. In addition, *p21* is frequently down-regulated in human cancer, and the loss of its expression or function has been implicated in Carcinogenesis or the prognosis of multiple cancers[@b12]--[@b17],[@b74]. However, studies also suggest that *p21* can promote the development of cancer, indicating a double-edged effect showing tumor-suppressing or tumor-promoting properties[@b9]--[@b11]. The most common *p21* polymorphism is at codon 31 (C \> A) within a highly conserved region of the gene, which causes an amino acid change from Ser to Arg and may encode functionally distinct proteins [@b23]. Although some functional studies suggest that *p21*-Ser and *p21*-Arg variant alleles present similar kinase inhibitory activity and growth suppression ability[@b19], they have been shown to differ significantly in their transcriptional efficiency. For example, individuals carrying the *p21*-Arg-encoding allele manifest a lower *p21* expression[@b75]. Our meta-analysis supports that individuals carrying the Arg/Arg genotype have a higher cancer risk as assessed in a recessive model.

![Funnel plot analysis to detect publication bias. Each point represents a separate study for the Indicated association.](cjc-30-04-254-g003){#cjc-30-04-254-g003}

Because of the paradoxical role of *p21* contributing to both cancer suppressive and promoting effects, it is biologically plausible that multiple tumors with different carcinogenic mechanisms may reflect different susceptibilities conferred by the *p21* Ser31Arg polymorphism. In our meta-analysis, we found that the effect of the *p21* 31Arg/Arg genotype was unfavorable toward the development of breast, head and neck, cervical, and colorectal cancer, but appeared to be favorable toward the development of lung, skin, gastric, and esophageal cancer. Heterogeneity analysis also showed that tumor type contributed to substantial between-study heterogeneity. Thus, inconsistent results among different cancers may involve the mechanisms by which *p21* regulates cell proliferation or apoptosis in different cancer cells. However, this difference could also be due to limited statistical power as a result of a small sample size in subgroup analysis. Recently, a meta-analysis investigated the association between the *p21* Ser31Arg polymorphism and breast cancer risk among 22 109 cases and 29 127 controls, but no significant associations were found[@b76], which is consistent with our results in breast cancer-including additional studies (22 656 cases and 30 133 controls). Moreover, studies have reported that estrogen stimulates cell mitotic activity and Carcinogenesis in breast, endometrial, and ovarian cancer[@b77],[@b78]. In subgroup analysis, we found that the *p21* Ser31Arg polymorphism was significantly associated with risk toward the development of estrogen-related cancer, possibly due to different carcinogenic mechanisms of different cancer types including gene-environment interactions.

Ethnicity may affect tumor susceptibility by different genetic factors and environmental exposures through gene-gene and gene-environment interactions. In our meta-analysis, we observed that the association between the *p21* 31Arg/Arg genotype and overall cancer risk was significant in Caucasians but not in Asians. Furthermore, our results indicated that the association of significantly increased cancer risk with the *p21* 31Arg/Arg genotype was more pronounced in studies with population-based controls, matching design, or larger sample sizes. The possible explanation may be that population-based controls were more representative of the general population and that studies with matching design or larger sample sizes may eliminate some bias and thus have a greater reliability or statistical power to detect the moderate effect of this single nucleotide polymorphism, suggesting that some characteristics should be carefully considered in genetic association studies, such as the selection of controls, matching status, ethnicity information, and sample size.

Several potential limitations of the present meta-analysis warrant consideration. First, although the funnel plot and Egger\'s test showed no publication bias, selection bias might have occurred because only studies published in English were included in our meta-analysis. Second, in the stratification analyses, the numbers of individuals carrying the Arg/Arg genotype in some subgroups were relatively small because of its low allele frequency in Caucasian subjects, which might have a small statistical power to detect the real association. Third, our results were based on unadjusted estimates, because ORs in all studies were not adjusted by the same potential confounders, such as age, sex, and exposure. Thus, a more precise analysis should be conducted, if individual data were available, which would allow for the adjustment by some co-variants and further evaluation of potential gene-environment interactions. In summary, this meta-analysis provides statistical evidence that the *p21* Ser31Arg polymorphism may contribute to individual susceptibility to cancer. Future well-designed large studies were warranted to validate our findings in different ethnic populations.
